The Lancet Oncology in conversation with
Общая длительность:
12 h 55 min
Tumour-infiltrating lymphocytes in breast cancer with Professor Sherene Loi
The Lancet Oncology in conversation with
17:49
5-year quality of life study of the SUPREMO trial examining chest wall radiotherapy in patients with intermediate-risk breast cancer with Professor Galina Velikova
The Lancet Oncology in conversation with
11:48
Hans Merks on European guidelines for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma
The Lancet Oncology in conversation with
12:39
Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission
The Lancet Oncology in conversation with
23:36
Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
The Lancet Oncology in conversation with
13:01
James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
The Lancet Oncology in conversation with
10:55
Ali Landman on the European Congress of Radiology 2026
The Lancet Oncology in conversation with
15:00
Kayleigh Bhangdia on breast cancer GBD study 2023
The Lancet Oncology in conversation with
18:23
Dylan Graetz and Erica Kaye on qualitative research in oncology
The Lancet Oncology in conversation with
42:58
Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers
The Lancet Oncology in conversation with
23:47
Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3
The Lancet Oncology in conversation with
26:34
Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission
The Lancet Oncology in conversation with
10:46
Matthias Preusser on the phase 2 TUXEDO-3 trial
The Lancet Oncology in conversation with
17:10
Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer
The Lancet Oncology in conversation with
12:15
Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas
The Lancet Oncology in conversation with
14:22
Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer
The Lancet Oncology in conversation with
07:36
Abdalla Awidi on cancer control in the Middle East
The Lancet Oncology in conversation with
08:22
ASCO 2025 Debrief
The Lancet Oncology in conversation with
14:45
Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial)
The Lancet Oncology in conversation with
10:45
Richard Bryant on transperineal vs transrectal biopsy for prostate cancer
The Lancet Oncology in conversation with
18:02
Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)
The Lancet Oncology in conversation with
07:33
Ariana Znaor on cancer surveillance in the Eastern Mediterranean region
The Lancet Oncology in conversation with
20:03
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials
The Lancet Oncology in conversation with
18:03
Yannick Romero on the changing landscape of national cancer control plans
The Lancet Oncology in conversation with
24:40
M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries
The Lancet Oncology in conversation with
22:15
Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma
The Lancet Oncology in conversation with
15:07
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination
The Lancet Oncology in conversation with
17:21
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics
The Lancet Oncology in conversation with
40:45
Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)
The Lancet Oncology in conversation with
13:22
Emmy Boerrigter on dose selection of novel anticancer drugs
The Lancet Oncology in conversation with
11:41
Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations
The Lancet Oncology in conversation with
36:56
Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment
The Lancet Oncology in conversation with
24:08
James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean
The Lancet Oncology in conversation with
35:05
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials
The Lancet Oncology in conversation with
11:22
Maria Kyrgiou on innovations in gynaecological cancers and global disparities
The Lancet Oncology in conversation with
25:42
Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers
The Lancet Oncology in conversation with
34:43
Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer
The Lancet Oncology in conversation with
16:06
Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma
The Lancet Oncology in conversation with
13:53
Neerja Bhatla on a new quadrivalent HPV vaccine
The Lancet Oncology in conversation with
12:24
Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery
The Lancet Oncology in conversation with
43:49
